Medline ® Abstract for Reference 18
of 'Treatment of androgenetic alopecia in men'
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B
J Am Acad Dermatol. 2007;57(5):767. Epub 2007 Aug 29.
BACKGROUND: An alternative to currently marketed topical minoxidil solutions is desirable.
OBJECTIVE: To assess the efficacy and safety of a new 5% minoxidil topical formulation in a propylene glycol-free foam vehicle in men with androgenetic alopecia (AGA).
METHODS: This was a 16-week, double-blind, placebo-controlled trial of 5% minoxidil topical foam (MTF) in 352 men, 18 to 49 years old. At week 16, 143 subjects continued on an open-label phase to collect 52 weeks of safety information on 5% MTF.
RESULTS: At week 16 compared with baseline, there was a statistically significant increase in (1) hair counts in the 5% MTF group versus placebo (P<.0001) and (2) subjective assessment of improved hair loss condition (P<.0001) in the 5% MTF group versus placebo. The 5% MTF was well tolerated over a 52-week period.
LIMITATIONS: There was no collection of efficacy data beyond 16 weeks.
CONCLUSIONS: We believe that 5% MTF is a safe and effective treatment for men with AGA.
Duke University Medical Center, Durham, North Carolina 27516, USA. email@example.com